Transgene Announces Financial Calendar for 2022
Category: Press release
Transgene announces Financial Calendar for 2022
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en
Transgene reports business update and Q3 2021 financial position
20211104 – Transgene – Q3 Financial update EN
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
BT-001 oncolytic virus at SITC 2021
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
